RxDoctor Payments Data

Jeffrey Parres, MD

Urology · Maryville, ILNPI 1619951027

Payments from drug & device makers

$8,882in general payments, 2019–2025

Across 266 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Myriad Genetic Laboratories, Inc.$702
  • Johnson & Johnson$511
  • Astellas Pharma US Inc$503
  • Procept Biorobotics Corporation$483
  • Sumitomo Pharma America, Inc.$473
  • plus $5K from 39 others

What the payments were for

  • Travel & lodging$93010%
  • Food & beverage$7,73487%
  • Education$2182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,882 in reported general payments places this provider in the 75th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$413,408
Medicare patients
938
Services billed
8,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide91$1,238,305
NubeqaDarolutamide23$318,449
GemtesaVibegron146$94,649
OrgovyxRelugolix33$89,323
MyrbetriqMirabegron105$62,909
Finasteride1,515$18,363
Tamsulosin Hcl849$10,323
Mirabegron ErMirabegron13$7,099
Oxybutynin Chloride ErOxybutynin Chloride344$5,821
Abiraterone Acetate36$4,690
ToviazFesoterodine Fumarate14$4,044
Cephalexin336$2,816
Potassium Citrate ErPotassium Citrate40$2,814
Testosterone Cypionate56$2,520
Dutasteride67$2,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$503$1,301,215196 claims
BayerNubeqa$244$318,44923 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$473$183,972179 claims
PfizerToviaz$367$4,04414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 550 urology providers in Illinois.

Other urology in Maryville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →